Upstream Bio, Inc. Files S-1/A for IPO

Ticker: UPB · Form: S-1/A · Filed: Oct 7, 2024 · CIK: 2022626

Upstream Bio, Inc. S-1/A Filing Summary
FieldDetail
CompanyUpstream Bio, Inc. (UPB)
Form TypeS-1/A
Filed DateOct 7, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$15.00, $17.00, $7.5 billion, $6.0 billion, $3.2 billion
Sentimentneutral

Sentiment: neutral

Topics: ipo, filing, pharmaceutical

TL;DR

Upstream Bio IPO filing updated. Get ready.

AI Summary

Upstream Bio, Inc. filed an amendment (S-1/A) on October 7, 2024, for its initial public offering. The company, incorporated in Delaware, is based in Waltham, MA, and operates in the pharmaceutical preparations sector. E. Rand Sutherland is the Chief Executive Officer, and Michael Paul Gray is the Chief Financial Officer.

Why It Matters

This S-1/A filing indicates Upstream Bio, Inc. is moving forward with its plan to become a publicly traded company, which could bring new investment and potentially new treatments to market.

Risk Assessment

Risk Level: medium — As a pre-IPO filing, the company's financial performance and future prospects are still largely unproven, carrying inherent investment risks.

Key Numbers

  • 333-282197 — SEC Registration Number (Identifies the specific registration for this offering.)

Key Players & Entities

  • Upstream Bio, Inc. (company) — Registrant
  • October 7, 2024 (date) — Filing Date
  • E. Rand Sutherland (person) — Chief Executive Officer
  • Michael Paul Gray (person) — Chief Financial Officer
  • Waltham, MA (location) — Principal Executive Offices
  • 333-282197 (registration_number) — SEC Registration Number

FAQ

What is the primary business of Upstream Bio, Inc.?

Upstream Bio, Inc. operates in the Pharmaceutical Preparations sector, SIC code 2834.

When was this amendment filed with the SEC?

This amendment (S-1/A) was filed on October 7, 2024.

Who are the principal executive officers mentioned in the filing?

E. Rand Sutherland is the Chief Executive Officer and Michael Paul Gray is the Chief Financial Officer.

Where is Upstream Bio, Inc. headquartered?

The company's principal executive offices are located at 890 Winter Street, Suite 200, Waltham, MA 02451.

What is the SEC file number associated with this registration?

The SEC file number is 333-282197.

Filing Stats: 4,433 words · 18 min read · ~15 pages · Grade level 15.1 · Accepted 2024-10-07 06:08:05

Key Financial Figures

  • $15.00 — ffering price is expected to be between $15.00 and $17.00 per share. Prior to this o
  • $17.00 — ce is expected to be between $15.00 and $17.00 per share. Prior to this offering, th
  • $7.5 billion — pe and Japan markets were approximately $7.5 billion. In December 2021, tezepelumab (markete
  • $6.0 billion — asthma is estimated to be approximately $6.0 billion. These statistics show there is a lar
  • $3.2 billion — ent of Translate Bio, Inc. prior to its $3.2 billion acquisition by Sanofi, and before that

Filing Documents

Risk factors

Risk factors 15 Special note regarding forward-looking statements 85 Market, industry and other data 87

Use of proceeds

Use of proceeds 88 Dividend policy 90 Capitalization 91

Managements discussion and analysis of financial condition and results of operations

Managements discussion and analysis of financial condition and results of operations 96

Business

Business 120 Management 178

Executive compensation

Executive compensation 189 Director compensation 202 Certain relationships and related party transactions 205 Principal stockholders 210

Description of capital stock

Description of capital stock 214 Shares eligible for future sale 220 Material U.S. federal income tax considerations for non-U.S. holders of common stock 222

Underwriting

Underwriting 227 Legal matters 240 Experts 240 Where you can find more information 240 Index to consolidated financial statements F-1 Through and including, 2024 (the 25th day after the date of this prospectus), all dealers effecting transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealers obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. Neither we nor the underwriters have authorized anyone to provide any information or make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or in any applicable free writing prospectus is current only as of the date on the front cover of this prospectus, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into Table of Contents possession of this prospectus must inform themselves about, and observe, any restrictions relating to the offering of the shares of common stock and the distribution of this prospectu

View Full Filing

View this S-1/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.